Follow The Filings

LYEL Lyell Immunopharma

Lyell Immunopharma earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 11 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by LYEL's executives, directors and 10% owners in the last 12 months, from their Form 4s

All LYEL insider trades
  • $25M bought by 2 insiders
  • $74K sold by 1 insider outside a trading plan
  • $274 sold by 1 insider under 10b5-1 plans
  1. Innovative Cellular Therapeutics Holdings Ltd 10% owner
    Planned sale
    $137 10 shares at $13.70 <0.1% of stake
    Traded Jul 17 Filed Jul 20
    ↗
  2. Innovative Cellular Therapeutics Holdings Ltd 10% owner
    Planned sale
    $137 10 shares at $13.73 <0.1% of stake
    Traded Jul 16 Filed Jul 17
    ↗
  3. ARCH Venture Partners IX, LLC 10% owner, +4 joint filers
    Buy
    $12.5M 488,090 shares at $25.61 +52% to stake
    Traded Mar 6 Filed Mar 9
    ↗
  4. Veronica Sanchez Bulis VP, Corporate Controller
    Sale
    $74K 2,072 shares at $35.80 23% of stake
    Traded Dec 24–30 Filed Jan 6
    ↗

Also filed in the last 12 months, not counted as buying or selling: 25 sales to cover taxes, 4 stock grants, and 4 other transactions.

SEC filings

Recent issuer filings from EDGAR, 12 shown.

Filed Form Detail Links
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.